Here are the 10-Q quarterly reports from Bio Essence Corp (BIOE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BIOE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIOE filings page.
Bio Essence Corp. reported a sharp turnaround for the six months ended June 30, 2026, posting net income of $475,450 versus a loss a year earlier, on a more than tripling of OEM service revenues to $1,295,248. Gross profit rose to $789,614, and operating income reached $495,085.
Total assets increased to $4,002,945, driven largely by the acquisition of the MediFlow AI software, recorded as $3,396,438 of intangible assets after amortization. The company issued 15,800,000 new common shares during the period, including 8,800,000 shares for $440,000 of cash and 7,000,000 shares valued at $3,500,000 for the software.
Despite profitability, Bio Essence had cash of only $675, a working capital deficit of $998,524, and an accumulated deficit of $9,077,623. Management states that these factors, along with dependence on additional financing, raise substantial doubt about the ability to continue as a going concern. The company also carries about $1.5 million in operating lease liabilities tied to a disputed facility lease and acknowledges that disclosure controls and internal control over financial reporting are not effective.
Bio Essence Corp. reported a sharp turnaround for the quarter ended March 31, 2026, driven by OEM services. Revenue rose to $500,537 from $22,189 a year earlier, all from OEM services, producing gross profit of $319,353.
The company moved from a net loss of $205,752 to net income of $205,373, helped by lower general and administrative expenses. Despite this, the balance sheet remains weak, with total assets of $789,032, current liabilities of $2,160,871, and a stockholders’ deficit of $1,427,520, and management discloses substantial doubt about continuing as a going concern.
During the quarter, Bio Essence raised $440,000 via issuance of 8,800,000 common shares at $0.05 per share and ended with cash of $36,177. It has accrued about $1.5M of lease-related liabilities tied to a disputed Irvine facility lease and faces an additional, unaccrued Statement of Work claim. Internal controls over financial reporting and disclosure controls are assessed as not effective.
Bio Essence Corp. filed its Q3 2025 10‑Q, showing stronger operating performance but ongoing financial strain. For the nine months ended September 30, 2025, revenue was $418,112 (up from $176,385), gross profit was $284,992, operating expenses were $414,608, and net loss from continuing operations narrowed to $132,890. For the quarter, revenue was $136,800 with $12,998 net income from continuing operations.
Liquidity remains tight: cash was $28,741, current liabilities were $3,230,021, and the working capital deficit was $3,045,643 as of September 30, 2025. The company reported $885,827 in loans from shareholders and $1,496,907 in current operating lease liabilities. Accumulated deficit reached $10,582,160. Management disclosed that these conditions raise substantial doubt about the ability to continue as a going concern and plans to seek additional financing.
Operations shifted toward OEM services, including a major order from a new customer, supporting revenue growth and margin improvement. Net cash provided by operating activities from continuing operations was $328,701, offset by $301,331 used in financing. Disclosure controls and ICFR were deemed not effective. Common shares outstanding were 38,009,000 as of the latest practicable date.